SIR-Spheres
SIR-Spheres is a medical device with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
Clinical Trials (7)
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
All 7 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 7